The tripartite motif-containing 37 (TRIM37) is a RING finger E3 ubiquitin ligase and is a poor
prognostic factor in breast cancer patients. The gene is located in chromosome 17q23, a …

Abstract Background: The oral cdk4/6 inhibitor, Palbociclib (Palbo), has been shown to
prolong progression-free survival when combined with anti-estrogen therapy and have …

Background: Dysregulation of the cyclin D-CDK4/6-Rb axis occurs in a substantial
proportion of ER-positive (ER+) breast cancers and has been linked with endocrine …

Purpose Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used for the
treatment of advanced estrogen receptor (ER)-positive breast cancer. To develop a …

Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting
Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway …

Background Breast cancer is a leading cancer in global women cancer incidence. Although
cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor combined with endocrine therapy is a …

Background Deregulation of the cyclin D-CDK4/6-INK4-RB pathway leading to uncontrolled
increased cell proliferation, is observed in various cancer types including breast cancer …

Introduction Resistance to cyclin inhibitors such as palbociclib is a challenge in the
treatment of hormone-dependent metastatic breast cancer. Likewise, triple negative tumors …

Estrogen receptor positive breast cancers show frequent deregulation of Cyclin D-CDK4/6
signaling. Combining CDK4/6 inhibitors with hormonal therapies produces clinical benefit …

Abstract Background: Combination of CDK4/6 inhibitors and endocrine therapy has been
shown to improve clinical outcome in advanced estrogen receptor-positive (ER+) breast …